Dental Asia May/June 2018

Dental Updates
New 3Shape and Oventus Integration Gets Patients Into Sleep Therapy Faster
New digital integration between
Oventus and the 3Shape TRIOS intraoral
scanner creates a faster devicemanufacturing
turnaround time to get
patients into sleep therapy faster.
The just-announced integration enables
dental professionals using the awardwinning
3Shape TRIOS intraoral scanner to
send digital impressions direct to Oventus
for the ordering and designing of its sleep
devices for snoring and sleep apnea.
3Shape TRIOS users can simply choose
Oventus from the more than 45 treatment
providers in the intraoral scanner’s menu to
instantly cloud-send the digital impressions
to Oventus.
According to Dr. Chris Hart, Clinical
Director and inventor of Oventus,
“ T h e d i g i t a l w o r k f l o w w i t h
3Shape TRIOS increases overall
efficiency in its production
workow, particularly quicker
turnaround times from start
to finish. This enables
patients with sleep apnea
to be treated more quickly,
which is appreciated by patients
and referring providers alike.”
The digital workow with 3Shape TRIOS
also increases accuracy, which in turn
means fewer remakes and less chair time for
patients, according to Oventus. Adding that
the digital workow eliminates analoguerelated
challenges such as impressions
being distorted because of gagging, tongue
thrusts, saliva contamination, shipping
temperature, or imprecise lab pour-ups.
“We are excited to bring
another terrific treatment
opportunity like Oventus to
doctors and their patients.
The digital workflow,
because of its accuracy, speed
and connectivity, makes it so
much easier for professionals
to provide quality care to their patients. As
more and more solutions choose to connect
with TRIOS, its accuracy, ease of use, and
open and expanding ecosystem, make it
the right choice for dental professionals,”
M r . A l l a n H y l d a l , V i c e P r e s i d e n t o f
3Shape Orthodontics.
2018 ADIA Research Grants Tackles Periodontitis
Pioneering research to address chronic
periodontitis has been awarded to the
Australian Dental Industry Association
Research Grant bestowed by the
Australian Dental Research Foundation (ADRF),
the nation’s leading funding body for earlycareer
researchers into dental and oral
health issues. The grant is funded by the
Australian Dental Industry Association (ADIA),
the peak business organisation representing
innovative dental product manufacturers
and suppliers.
The most recent award was provided to
Associate Professor Neil O’Brien-Simpson
from the University of Melbourne
Dental School into research associated
with antimicrobial peptides that target
periodontal pathogens. He’s a project
manager for the Oral Health Cooperative
Research Centre. The research project
will be supported by Dr. Jason Lenzo
a n d D r . J a m e s H o l d e n , b o t h f r o m t h e
Melbourne Dental School.
The research seeks to address chronic
periodontitis, an inflammatory disease
associated with a pathogenic subgingival
bacteria leading to the destruction of the
tooth’s supporting tissues and ultimately
tooth loss. It is a major public health
problem in all societies and is estimated to
aect at least 30% of the adult population,
including 5% to 6% who experience severe
forms of the disease. The prevention of
chronic periodontitis relies on removing
the bacterial burden by effective tooth
cleaning, sometimes in combination with
antibiotics and/or antiseptics; however,
long-term use of antibiotics is undesirable
due to the emergence of resistant bacteria.
Indeed, several reports have highlighted
an increasing trend towards antibiotic
resistance in oral bacteria.
The increasing reports of multi-drug and
antibiotic resistant bacteria and the limits on
the use of antiseptics, such as chlorhexidine,
have resulted in extensive research to
discover and develop new and novel classes
of antimicrobials that are eective and safe
for human use.
“The objectives of the research
a l i g n w i t h t h e c o n d i t i o n s o f t h e
Australian Dental Industry Association
Research Grant that provides
funding for projects that may,
following commercialisation, support
the development of new and/or
innovative dental and oral healthcare
treatment pathways or products,” said
Mr. Troy Williams, ADIA Chief Executive
Ocer.
The Australian Dental Industry
Association Research Grant provides
funding to explore the potential of a
n o v e l c l a s s o f a n t i b i o t i c s c a l l e d
antimicrobial peptides (AMP). The research
team have already identied several AMPs
by altering their sequence and adding
chemical moieties that reduce toxicity
to mammalian cells while targeting and
enhancing antibacterial activity towards
periodontal pathogens.
“ADIA has a long track-record of
supporting the development of innovative
patient diagnostic and treatment
options and it’s in this context that we’re
c o mm i tted to th e lo n g -term fu n di n g o f th e
Australian Dental Industry Association
Research Grant is funded,” Mr. Williams
said.
10 DENTAL ASIA
MAY / JUNE 2018